Aprogen gets OK Phase 3 trials in India for Herceptin biosimilar
The S.Korean biopharmaceutical company seeks FDA approval for clinical trials of breast cancer treatment AP063
By Feb 05, 2024 (Gmt+09:00)
S.Korea's LS Materials set to boost earnings ahead of IPO process
Hankook Tire buys $1 bn Hanon Systems stake from Hahn & Co.
Aman, Rosewood, Banyan, IHG rush to open luxury hotels in Seoul
Samsung Heavy Industries succeeds autonomous vessel navigation
Biden exempts graphite from EV mineral sourcing rule in win for Korea
South Korea’s biopharmaceutical company Aprogen Inc. announced on Monday that its Phase 3 clinical trial for a biosimilar of Herceptin (trastuzumab) AP063 got approval from to India's Central Drugs Standard Control Organization (CDSCO).
These trials aim to demonstrate the equivalence of AP063 to Herceptin in terms of efficacy, safety, and immunogenicity (the ability to induce an immune response).
In November last year, Aprogen submitted an identical application for phase 3 trials to India's CDSCO.
"We plan to file for marketing approval not only in India but also with the US Food and Drug Administration (FDA) and other countries beyond Europe," an Aprogen source said.
Write to In-Hyuk Park at hyuk@hankyung.com
-
Bio & PharmaCelltrion Healthcare's Herzuma selected as funded brand in NZ
Dec 07, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaPrestige Bio's Herceptin biosimilar proves equivalence in clinical trials
Feb 08, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaCelltrion wins sales approval for biosimilar Vegzelma in Japan
Sep 27, 2022 (Gmt+09:00)
1 Min read